Amgen announced results from a pre-specified retrospective analysis of patients with metastatic melanoma that showed talimogene laherparepvec reduced the size of injected tumors and non-injected metastasized tumors.
The analysis included about 4,000 tumor lesions from a Phase 3 study that evaluated talimogene laherparepvec in patients with injectable unresected Stage IIIB, IIIC or IV melanoma compared to granulocyte-macrophage colony-stimulating factor (GM-CSF). In the study, half of the lesions were injected with talimogene laherparepvec at least once, while the rest were non-injected, including visceral tumor lesions. Study results showed a >50% reduction in tumor size in 64% of injected tumors. In addition, 1/3 of non-injected non-visceral tumors, and 15% of visceral tumors were also reduced by >50%.
Talimogene laherparepvec is an investigational oncolytic immunotherapy designed to selectively replicate in tumor tissue and to initiate a systemic anti-tumor immune response. Talimogene laherparepvec is also designed to express GM-CSF, a white blood cell growth factor.
For more information call (800) 77-AMGEN or visit Amgen.com.
This article originally appeared on MPR